RenovoRx, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $59.5M
- Price
- $1.32
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.38%
- Volume
- 381.2K
About
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Quick stats
Shares outstanding45.1M
Computed float36.7M
Float / shares81.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001574094
Websitehttps://renovorx.com
AI Summary
AI-generated1/23
minorbullishoperations update
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
RenovoRx announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering its RenovoCath dual-occlusion catheter and TAMP platform.
The newly allowed claims cover the proprietary catheter system designed for targeted oncology drug delivery, bringing the company's total IP portfolio to 20 issued or allowed patents and 13 pending applications.
RenovoCath commercialization continues with approximately $1.1 million in sales for 2025 and $1.5 million year-to-date as of June 30, 2026, while the Phase III TIGeR-PaC trial for the IAG combination product remains ongoing.